Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14444123 | 0.83 | AHR (0.39) | KCNA3SMN1; SMN2HSD17B10MAPTPOLB | |
| SCHEMBL20793964 | 0.80 | SMN1; SMN2 (0.53) | KCNA3SMN1; SMN2PSMB5HSD17B10MAPT | |
| SCHEMBL4419414 | 0.79 | CES1 (0.39) | KCNA3SMN1; SMN2HSD17B10MAPTPOLB | |
| SCHEMBL22645755 | 0.77 | TP53 (0.35) | KCNA3SMN1; SMN2PSMB8PSMB5MAPT | |
| SCHEMBL20793965 | 0.77 | SMN1; SMN2 (0.35) | KCNA3SMN1; SMN2HSD17B10POLBTHRB | |
| SCHEMBL21387019 | 0.75 | SMN1; SMN2 (0.38) | KCNA3SMN1; SMN2HSD17B10POLBTSHR | |
| SCHEMBL2095750 | 0.75 | CYP1A2 (0.42) | KCNA3PSMB8PSMB5MAPTPOLB | |
| SCHEMBL12279309 | 0.75 | HSD17B10 (0.38) | KCNA3SMN1; SMN2HSD17B10MAPTTSHR | |
| SCHEMBL20111022 | 0.75 | HSD17B10 (0.38) | KCNA3SMN1; SMN2HSD17B10MAPTTSHR | |
| SCHEMBL4163346 | 0.73 | AHR (0.39) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-3672977-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-20210317145-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| WO-2020020858-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019038250-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317145-A1 | Boronic Acid Derivatives | PSMB7, PSMA7, BRD7 | KCNA3 4266/4885SMN1; SMN2 980/4885PSMB8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.